Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.56 |
| ▸ | AURKA | O14965 | 12/20 | 0.56 |
| ▸ | TEK | Q02763 | 12/20 | 0.56 |
| ▸ | LCK | P06239 | 10/20 | 0.56 |
| ▸ | MET | P08581 | 10/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.56 |
| ▸ | FLT1 | P17948 | 4/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.49 |
| ▸ | LYN | P07948 | 3/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.49 |
| ▸ | FLT4 | P35916 | 2/20 | 0.49 |
| ▸ | PDXK | O00764 | 1/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | FGR | P09769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316349 | 0.95 | KDR (0.57) | KDRAURKATEKLCKMET | |
| SCHEMBL6309412 | 0.92 | KDR (0.57) | KDRAURKATEKLCKMET | |
| SCHEMBL6309729 | 0.89 | KDR (0.61) | KDRAURKATEKLCKMET | |
| SCHEMBL5241805 | 0.81 | KDR (0.42) | KDRFLT1 | |
| SCHEMBL6315836 | 0.79 | KDR (0.54) | KDRAURKATEKLCKMET | |
| SCHEMBL6315261 | 0.78 | KDR (0.51) | KDRAURKATEKLCKMET | |
| SCHEMBL6310032 | 0.76 | KDR (0.54) | KDRAURKATEKLCKMET | |
| SCHEMBL5243529 | 0.76 | KDR (0.44) | KDRFLT1 | |
| SCHEMBL6315302 | 0.73 | KDR (0.49) | KDRAURKATEKLCKMET | |
| SCHEMBL5774867 | 0.73 | KDR (0.83) | KDRAURKATEKLCKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | claimed |
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | AGOURON PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070508-A1 | Napthalene carboxamides and their derivatives useful as new anti-angiogenic agents | CCNA1, CCNA2, CCNT1 | KDR 30/4885AURKA 2306/4885TEK 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.